14051-72-0

Basic information

• Product Name: N~6~-phenyl-5H-purine-2,6-diamine
• CAS NO: 14051-72-0
• Molecular Formula: C₁₁H₁₀N₆
• Molecular Weight: 226.2373
• Mol File: 14051-72-0.mol
• Article Data: 7

Chemical Properties

• Boiling Point: 402.6°C at 760 mmHg
• Flash Point: 197.3°C
• Density: 1.56g/cm³
• Vapor Pressure: 1.08E-06mmHg at 25°C
• Refractive Index: 1.817
• CAS DataBase Reference: N~6~-phenyl-5H-purine-2,6-diamine(CAS DataBase Reference)
• NIST Chemistry Reference: N~6~-phenyl-5H-purine-2,6-diamine(14051-72-0)
• EPA Substance Registry System: N~6~-phenyl-5H-purine-2,6-diamine(14051-72-0)

Safety Data

• Hazardous Substances Data: 14051-72-0(Hazardous Substances Data)

Upstream product

• 122-51-0 orthoformic acid triethyl ester 
• 73-40-5 2-amino-1,9-dihydro-6H-purin-6-one 
• 542-11-0 aniline hydrobromide 
• 62-53-3 aniline 
• 10310-21-1 2-Amino-6-chloropurin 
• 97965-44-1 2-acetamido-9-acetyl-6-chloropurine 
• 73-40-5 2-amino-6-hydroxypurine 
• 10310-21-1 2-amino-6-chloropurine 

Downstream Products

• 151643-85-5 2-amino-9-(2,3-dideoxy-3-fluoro-β-D-erythro-pentofuranosyl)-6-phenylamino-9H-purine 

Relevant articles and documents

Application of five-membered heterocycle pyrimidine compound

The invention belongs to the field of medicine and particularly relates to application of a five-membered heterocycle pyrimidine compound with the structural features as shown in formula (I) and the pharmaceutically acceptable salt of the five-membered heterocycle pyrimidine compound serving as nucleotide oxidative damage repairase MTH1 inhibitors. Pharmacological experiment results show that thecompound can evidently inhibit the activity of MTH1 and can be used for preventing and treating clinical diseases related to MTH1.

Method for treating disease or condition susceptible to amelioration by AMPK activators and compounds of formula which are useful to activate AMP-activated protein kinase (AMPK)

The present invention relates to a method for treating disease or condition susceptible to amelioration by AMPK activators and compounds of formula which are useful to activate AMP-activated protein kinase (AMPK) and the use of the compounds in the prevention or treatment of disease, including pre-diabetes, type 2 diabetes, syndrome X, metabolic syndrome and obesity.

SUBSTITUTED 6-ANILINOPURINE DERIVATIVES AS INHIBITORS OF CYTOKININ OXIDASE/DEHYDROGENASE AND PREPARATIONS CONTAINING THESE DERIVATIVES

The invention relates to substituted 6-anilinopurine derivatives of the general formula I, wherein R denotes one to five substituents independently selected from the group consisting of hydrogen, halogen, hydroxyl, amino, alkyloxy and alkyl group, and R2 denotes amino, halogen, nitro, thio, alkylthio or alkyl group for use as inhibitors of cytokinin oxidase/dehydrogenase. The invention also relates to the compositions containing these derivatives.